Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 14, 2023 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

NEWTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...
August 21, 2019 16:30 ET | Source: BeiGene, LTD.

BeiGene Announces U.S. FDA Acceptance and Grant of Priority Review for its New Drug Application of Zanubrutinib in Patients with Relapsed/Refractory Mantle Cell Lymphoma

CAMBRIDGE, Mass. and BEIJING, China, Aug. 21, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
June 14, 2019 02:30 ET | Source: BeiGene, LTD.

BeiGene Announces Clinical Results from Three Posters on Zanubrutinib Presented at the 24th Congress of European Hematology Association (EHA)

First Preliminary Data from Exploratory MYD88WT Patient Cohort in Phase 3 Trial in Waldenström’s Macroglobulinemia (WM); Updated Phase 1/2 WM Data; and Pooled Safety Data Analysis on Zanubrutinib in...
February 19, 2019 16:30 ET | Source: BeiGene, LTD.

BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma

CAMBRIDGE, Mass. and BEIJING, China, Feb. 19, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
January 14, 2019 16:15 ET | Source: BeiGene, LTD.

BeiGene Receives U.S. FDA Breakthrough Therapy Designation for Zanubrutinib in Mantle Cell Lymphoma

CAMBRIDGE, Mass. and BEIJING, China, Jan. 14, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
December 01, 2018 15:45 ET | Source: BeiGene, LTD.

BeiGene Announces Clinical Results of Zanubrutinib in Mantle Cell Lymphoma From Two Presentations at the 60th American Society of Hematology Annual Meeting

CAMBRIDGE, Mass. and BEIJING, China, Dec. 01, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
December 09, 2017 09:00 ET | Source: BeiGene, LTD.

BeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with GAZYVA® (Obinutuzumab) at the 59th American Society of Hematology Annual Meeting

CAMBRIDGE, Mass. and BEIJING, China, Dec. 09, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
July 18, 2016 16:00 ET | Source: ArQule, Inc.

ArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and Mutant BTK, at the 2016 Pan Pacific Lymphoma Conference

Data supports further preclinical and clinical research in BTK sensitive and ibrutinib resistant malignancies BURLINGTON, Mass., July 18, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today...
February 29, 2016 07:00 ET | Source: ArQule, Inc.

ArQule Reports Fourth Quarter and Full Year 2015 Financial Results

Conference Call Scheduled Today at 9:00 a.m. ET BURLINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced its financial results for the fourth quarter and...